In short
Clinical trials are investigating SOVATELTIDE in people with acute cerebral ischemic stroke. These studies aim to assess safety and efficacy, especially whether treatment improves recovery after stroke. The available trial data focus on adults with this condition in a Phase 3 study.
Key points
- SOVATELTIDE is being studied in a Phase 3 clinical trial for acute cerebral ischemic stroke. The trial is authorised and plans to include 452 participants. Researchers are comparing SOVATELTIDE with a matching placebo. The main goal is to see whether more patients have a good recovery by day 90 after randomization. Recovery is measured with the modified Rankin Scale, where a score of 0 to 2 means a better functional outcome.
Trial overview
The available clinical trial data show one interventional study of SOVATELTIDE in people with acute cerebral ischemic stroke. The study is designed to assess both safety and efficacy, which means the researchers want to see whether the treatment can help recovery and how well it performs in the study setting.
Who is being studied
The target condition is acute cerebral ischemic stroke, a sudden stroke caused by blocked blood flow to the brain. The trial data do not provide more detailed eligibility rules, so the main population described is patients with this condition.
Study design and treatment groups
This study is a Phase 3 trial, which is a later-stage study that usually tests how well a treatment works in a larger group of people. Participants are assigned to receive either SOVATELTIDE or a matching placebo, so the researchers can compare outcomes between the two groups.
The trial lists SOVATELTIDE as an intravenous treatment at 0.9 µg/Kg, and the comparison arm uses a matching placebo. An intravenous treatment is given through a vein.
What the trial measures
The main endpoint, also called the primary efficacy endpoint, is the proportion of patients with a good functional outcome on day 90 after randomization. A good functional outcome is defined as a modified Rankin Scale score of 0 to 2.
The modified Rankin Scale (mRS) is a stroke recovery scale used to measure disability and independence in daily life. In this study, lower scores mean better recovery, and a score of 0 to 2 is considered a favorable result.
Trial status and size
The trial status is listed as Authorised. The planned enrollment is 452 participants, which gives the study enough size to compare recovery results across the groups.
Only one clinical trial is provided in the source data, so the article focuses on this single Phase 3 study of SOVATELTIDE in acute cerebral ischemic stroke.